Clinical trials: Aphasia Primary Progressive
Alzheimer Disease, Primary Progressive Aphasia
Identification of Graphic Markers of Neurocognitive Disorders (MG)
The diagnosis of neurocognitive disorders such as early Alzheimer's disease (AD) or primary progressive aphasia (PPA) is particularly difficult and constantly evolving, often leading to diagnostic erraticity.
- Conditions
- Alzheimer Disease, Primary Progressive Aphasia, Neurocognitive Disorders
- Trial name
- MG (NCT05537688)
- Testing
- Identification of Graphic Markers
- Where
- Canada
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal
Progressive Supranuclear Palsy (PSP)
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy
This is a phase 1, multi-center, double-blind, placebo-controlled, multiple dose escalation study with NIO752 in progressive supranuclear palsy (PSP) participants.
- Trial name
- NCT04539041
- Testing
- antisense oligonucleotide
- Where
- 12 sites in United States, Canada and 2 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
Biodistribution of 11C-PIB PET in Alzheimer's Disease, Frontotemporal Dementia, and Cognitively Normal Elderly
Alzheimer's disease (AD) is characterized by neuritic plaques, neurofibrillary tangles, and neuronal cell loss. Amyloid plaques are believed to play an integral role in AD.
- Trial name
- 11C-PIB PET (NCT00811122)
- Testing
- 11C-PIB PET Scan, FDG-PET Scan
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- University of Utah
Frontotemporal Dementia
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
This is a Phase 1/2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of DNL593 in two parts…
- Trial name
- NCT05262023
- Testing
- DNL593
- Where
- 26 sites in United States, Belgium and 10 more
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Denali Therapeutics Inc.
Asmd, Visceral Type
Magnetic Resonance Spectroscopy in Acid Sphingomyelinase Deficiency
The goal of this study is to assess the ability of MRI techniques to detect early stages of lipid accumulation in the liver of ASMD patients with the chronic visceral subtype compared to healthy subjects.
- Trial name
- MONACO (NCT05904366)
- Testing
- MR Spectroscopy (MRS), MR Elastography (MRE)
- Where
- Netherlands
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Eline C. B. Eskes
Semantic Dementia
Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology
The purpose of the study is to test the safety and tolerability of twice daily Verdiperstat in patients with semantic variant primary progressive aphasia (svPPA) due to frontotemporal lobar degeneration with TDP-43 pathology…
- Trial name
- Veri-T-001 (NCT05184569)
- Testing
- Verdiperstat
- Where
- 5 sites in United States
- Volunteers
- 64 people
- Sponsor
- Peter Ljubenkov, MD
Alzheimer Disease, Parkinson Disease
Research Study for Patients With Neurological Diseases Which Evaluates the Patient Experience of the MemorEM Device
Primary Objective: The primary objective of this pilot study is to gain voluntary feedback from patients with neurological diseases and their caregivers regarding their experiences using the MemorEM head device.
- Conditions
- Alzheimer Disease, Parkinson Disease, Frontotemporal Dementia, Cortico Basal Degeneration
- Trial name
- MemorEM (NCT07222605)
- Testing
- MemorEM
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- eQ8Health Corporation d/b/a CareONE Concierge
Primary Progressive Aphasia, Logopenic Progressive Aphasia
Transcranial Direct Current Stimulation in the Treatment of Primary Progressive Aphasia
While many have strongly suggested that transcranial direct current stimulation (tDCS) may represent a beneficial intervention for patients with primary progressive aphasia (PPA), this promising technology has not yet been…
- Conditions
- Primary Progressive Aphasia, Logopenic Progressive Aphasia, Non-Fluent Primary Progressive Aphasia
- Trial name
- NCT05386394
- Testing
- Active tDCS + Language Therapy
- Where
- 3 sites in United States, Canada
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Alzheimer's Disease (AD), Parkinson's Disease (PD)
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
The goal of this study is to assess [18F]MNI-777 PET imaging as a tool to detect tau pathology in the brain of individuals who carry a clinical diagnosis of a tauopathy, including: Alzheimer's Disease (AD),Parkinson's disease…
- Conditions
- Alzheimer's Disease (AD), Parkinson's Disease (PD), Chronic Traumatic Encephalopathy (CTE), Progressive Supranuclear Palsy (PSP)
- Trial name
- NCT02103894
- Testing
- [18F]T807 ([18F]MNI-777)
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Alzheimer Disease, Lewy Body Dementia (LBD)
The Role of Advanced Electroencephalographic Data as Marker of Pathology and Prognosis in Primary Dementias
The study aims to use advanced brainwave recordings of electroencephalogram (EEG) to understand early signs of Alzheimer's disease (AD) in people with mild memory problems, known as amnestic Mild Cognitive Impairment (MCI).
- Conditions
- Alzheimer Disease, Lewy Body Dementia (LBD), Mild Alzheimer Disease, Frontotemporal Dementia (FTD)
- Trial name
- NCT06826157
- Testing
- Electroencephalogram, 3 Tesla MRI, Apolipoprotein E genetic test
- Where
- Italy
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Alzheimer's Disease, Primary Progressive Non-fluent Aphasia
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
The purpose of this study is to determine safety, tolerability, and pharmacokinetics/dynamics of a ketogenic dietary supplement containing medium chain triglycerides (MCTs) in patients with Alzheimer disease (AD).
- Conditions
- Alzheimer's Disease, Primary Progressive Non-fluent Aphasia, Frontotemporal Dementia (FTD)
- Trial name
- MINT-01 (NCT02912936)
- Testing
- Ketogenic medium chain triglyceride drink (MCT drink)
- Where
- Canada
- Volunteers
- 43 people
- Sponsor
- University of British Columbia
Niemann-Pick Disease, Type C
Longitudinal Study of Cognition With Niemann-Pick Disease, Type C
Niemann-Pick Disease, Type C (NPC) is a rare neurodegenerative disorder with a wide clinical spectrum and variable age of onset.
- Trial name
- NPC (NCT01899950)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Mayo Clinic
Alzheimer's Disease, Mild Cognitive Impairment
A Composite MR Neuroimaging Marker for Alzheimer's Disease
The purpose of this study is to use a functional MRI (fMRI) index to compare the brain activity of healthy volunteers to that of people with mild cognitive impairment (MCI) and Alzheimer's disease.
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Frontotemporal Dementia
- Trial name
- NCT01615666
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Medical College of Wisconsin
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)
Background: Amyotrophic lateral sclerosis (ALS) is a disorder that damages nerve cells in the brain and spinal cord. It can cause muscle weakness, paralysis, and loss of movement. The symptoms grow worse over time.
- Trial name
- NCT07204977
- Testing
- Acamprosate calcium
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Mild Cognitive Impairment
Diagnosis of Alzheimer's Disease Using Event Related Potentials
This study evaluates the use of an EEG device using Event Related Potentials to help diagnose Alzheimer's Disease in the outpatient clinical setting.
- Trial name
- NCT02957227
- Testing
- No intervention is part of this study but patients use an EEG device during observational data collection.
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- VA Boston Healthcare System
Post-stroke Cognitive Impairment, Neuroinflammation
The Influence of [18F]PMPBB3 and [18F]THK5351 PET Distribution Patterns on Post-stroke Cognitive Impairment
Background and objects： Neuroinflammation is an active process detectable in the earliest stages of the neurodegeneration pathway.
- Trial name
- NCT04318626
- Testing
- PMPBB3, THK5351
- Where
- Taiwan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Alzheimer Disease, Dementia
Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia
The current study aims to examine the benefits of an education/support group program for individuals with progressive aphasia (caused by various etiologies, diagnoses) and their carepartners.
- Conditions
- Alzheimer Disease, Dementia, Primary Progressive Aphasia, Aphasia
- Trial name
- NCT06511752
- Testing
- Psychosocial educational, support group and implementation of strategies
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Texas at Austin
Frontotemporal Dementia, Progressive Supranuclear Palsy
Study of the Neural Basis of Analogical Reasoning
Frontal patients are impaired in categorisation and analogical reasoning tasks, and different functional imaging studies from our group have shown the involvement of the prefrontal cortex in categorisation and analogy tasks.
- Conditions
- Frontotemporal Dementia, Progressive Supranuclear Palsy, Healthy Subjects
- Trial name
- ANALOG (NCT02236832)
- Testing
- transcranial magnetic stimulation, MRI imaging, EEG recording
- Where
- France
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP)
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American…
- Conditions
- Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD)
- Trial name
- NCT04363684
- Where
- 26 sites in United States, Canada
- Volunteers
- 2,100 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Parkinson Disease, Amyotrophic Lateral Sclerosis (ALS)
Discovery and Validation of Protein Structural Complexes in Circulating Biofluids As Novel Biomarkers for Early Diagnosis, Prognosis and Therapeutic Management of Patients Affected by Neurodegenerative Disorders
Neurodegenerative disorders (NDDs), such as Parkinson¿s disease (PD), Alzheimer¿s disease (AD), Frontotemporal dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS) are characterized by aggregation and intracellular accumulation…
- Conditions
- Parkinson Disease, Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Alzheimer's Disease (AD)
- Trial name
- NCT06803784
- Testing
- Genetic: whole genome sequencing, whole exome sequencing
- Where
- Italy
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Neuromed IRCCS